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Increased macula densa cyclooxygenase-2 (COX-2) is
observed in diabetic rats and may contribute to
hyperfiltration states. However, the signals mediating
increased COX-2 expression in diabetic rats remain
undetermined. We recently found that non-proteolytic
activation of prorenin by site-specific binding proteins, such
as prorenin receptor, plays a pivotal role in the development
of diabetic nephropathy. The present study was designed to
determine the contribution of prorenin receptor to renal
cortical COX-2 expression. The COX-2 mRNA and protein
levels of six 4-week-old male wild-type rats and six human
prorenin receptor gene-transgenic (hProRenRcTg) rats were
measured by real-time polymerase chain reaction methods,
Western blotting, and immunohistochemistry, and
compared. There were no differences between the two
groups in arterial pressure measured by telemetry, urinary
sodium excretion, or renal levels of rat prorenin receptor
mRNA. The renal cortical COX-2 mRNA levels of the
hProRenRcTg rats were significantly higher than those of the
wild-type rats, and the renal cortical COX-2 protein levels
were also higher in hProRenRcTg rats than in the wild-type
rats. Immunohistochemical analysis revealed that COX-2
immunostaining was predominantly present in the macula
densa cells, and significantly more COX-2-positive cells were
present in the hProRenRcTg rats than in the wild-type rats. In
addition, COX-2 inhibition with NS398 significantly decreased
renal cortical blood flow in the hProRenRcTg rats but not in
the wild-type rats. These results strongly suggest that human
prorenin receptor directly or indirectly contributes to the
regulation of renal cortical COX-2 expression.
Kidney International (2006) 70, 641–646. doi:10.1038/sj.ki.5001627;
published online 28 June 2006
KEYWORDS: cyclooxygenase; microcirculation; kidney; renal circulation;
renin
Cyclooxygenase-2 (COX-2) is constitutively present in the
macula densa cells and in medullary interstitial cells of the
kidney.1,2 COX-2 activity in the macula densa is stimulated
by high renal perfusion pressure,3 and the stimulated macula
densa COX-2 catalyzes the synthesis of vasodilator prosta-
glandins counteracting the tubuloglomerular-feedback-
mediated afferent arteriolar constriction.4 Thus, increased
activity of macula densa COX-2 can elicit a decrease in
afferent arteriolar resistance, which leads to elevation of
intraglomerular pressure.5
Recent studies have shown increased expression of macula
densa COX-2 in the kidneys of diabetic humans6 and rats.7
Because dilated afferent arterioles and enlarged glomeruli
are observed in the early stage of diabetic nephropathy, the
increased expression of macula densa COX-2 may account
for the hyperfiltration state of the glomeruli owing to afferent
arteriolar dilation in diabetic kidneys. As glomerular
hyperfiltration is well known to play an important role in
the development of diabetic nephropathy, macula densa
COX-2 may contribute to the development of nephropathy in
diabetic kidneys. However, the mechanism of the upregula-
tion of macula densa COX-2 expression in diabetic kidneys
remained unknown.
We recently found that site-specific prorenin-binding
proteins, such as prorenin receptor,8 contribute to the
development of diabetic nephropathy,9 and we therefore
hypothesized that the activation of prorenin receptor also
contributes to the mechanism of the increased expression of
COX-2 in the macula densa in diabetic kidneys. To test this
hypothesis, in the present study we assessed the expression
and function of renal cortical COX-2 in rats expressing a high
level of human prorenin receptor (hProRenRc).
RESULTS
Figure 1 shows that hProRenRc transgene was distributed
to various tissues including brain, heart, kidney, liver,
aorta, femoral artery, testis, lung, spleen, pancreas, adipose
tissue, adrenal gland, ovary, and uterus. In the kidneys of
hProRenRc-transgenic (Tg) rats, the majority of hProRenRc
transgene was present in tubular cells, and a few were
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observed in the glomerular epithelium. As shown in Table 1,
there were no significant differences in mean atrial pressure
(MAP), urinary sodium excretion, plasma renin activity,
plasma angiotensin II level, kidney angiotensin II level, renal
plasma flow, and rat prorenin receptor (rProRenRc) mRNA
levels between the Tg and wild-type rats. The microhemato-
crit of blood samples from wild-type and Tg rats was also
similar and remained constant throughout the experiment.
Urinary prostaglandin E2 was significantly higher in Tg rats
than in wild-type rats. The mRNA expression of hProRenRc
was detected only in Tg rats.
Renal cortical COX-2 expression
Figure 2a shows the COX-2 mRNA levels in the renal cortex
of the Tg and wild-type rats determined quantitatively by
a real-time polymerase chain reaction method. Renal
cortical COX-2 mRNA level in the Tg rats was 5.3370.70
(ratio to glyceraldehyde-3-phosphate dehydrogenase mRNA)
and was significantly higher than in the wild-type rats
(1.2870.66 (ratio to glyceraldehyde-3-phosphate dehydro-
genase mRNA)).
Figure 2b shows the COX-2 protein levels in the renal
cortex of the Tg and wild-type rats determined by Western
blot analysis. Renal cortical COX-2 protein levels (1.0670.26
(ratio to a-tubulin)) were also higher in Tg rats than in the
wild-type rats (2.1870.17 (ratio to a-tubulin)).
Immunostaining of renal cortical COX-2
Figure 3 shows the results of immunostaining with anti-rat
COX-2 antibody in the renal cortex of the Tg and wild-type
rats. Strong COX-2 immunostaining was observed in the
macula densa cells of the hProRenRcT rats, but weak staining
in the renal cortex of the wild-type rats.
Effects of COX-2 inhibition on renal blood flow and renal
cortical blood flow
Both the Tg and wild-type rats had a similar value of renal
blood flow because they had similar values of renal plasma
flow, as shown in Table 1, and microhematocrit throughout
the experiment. Figure 4 shows the effects of the COX-2
inhibitor NS398 on renal blood flow assessed by an
electromagnetic flow probe and renal cortical blood flow in
the Tg and wild-type rats. There were no significantly
changes in MAP in either group during COX-2 inhibition
with NS398. Under anesthesia, MAP at the beginning and
end of the study period measured 12273 and 11776 mm
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Figure 1 | Transgene of human protein receptor (hProRenRC).
(a) Representative semiquantitative RT-PCR products of hProRenRc
gene and its quantitative analysis by real-time RT-PCR in the various
tissues of no. 21 line (’) and no. 29 line (&) of Tg rats. (b) Renal
localization of hProRenRc transgene assessed by in situ hybridization
in wild-type (wild) rats and Tg rats with antisense and sense probes.
The high magnification photograph shows that the majority of
the transgene was expressed in tubular cells including macula densa
as shown by a big arrow, and a few were observed in the glomerular
epithelium as shown by small arrows.
Table 1 | Characterization of hProRenRc gene-transgenic (Tg) rats
Wild Tg P-value
Number 6 6
MAP (mm Hg) 8872 8871 0.54
UNaV (mEq/day) 3.6770.19 3.5870.30 0.84
Urinary PGE2 (ng/h) 20.371.8 33.772.0 o0.001
Microhematocrit (%) 54.371.7 52.370.9 0.30
PRA (ng/ml/h) 3.370.9 (n=4) 2.570.6 (n=19) 0.43
Plasma Ang II (fmol/l) 48.677.2 (n=14) 37.376.5 (n=19) 0.26
Kidney Ang II (fmol/g) 53.777.8 40.179.0 0.30
Renal plasma flow (ml/min/g) 5.770.6 5.470.5 0.81
Kidney rProRenRc mRNA (ratio to rat GAPDH mRNA) 6.970.5 6.870.4 0.88
Data are shown as means7s.d.
Ang II, angiotensin II; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MAP, mean arterial pressure; PGE2, prostaglandin E2; PRA, plasma renin activity; rProRenRc, rat
prorenin receptor; UNaV, urinary sodium excretion.
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Hg, respectively, in the wild-type rats, and 11872 and
12073 mm Hg, respectively, in the Tg rats. NS398 did not
significantly alter renal blood flow or renal cortical blood
flow in the wild-type rats; however, the 1 and 10 ng/g bw
(gram body weight) doses of NS398 significantly reduced the
renal blood flow of the Tg rats from 2.9170.23 to 2.3970.19
and 2.0370.41 ml/min, respectively, and decreased the renal
cortical blood flow of the Tg rats by 27.273.6 and
42.377.9%, respectively. The decreases in renal blood flow
and renal cortical blood flow in the Tg rats compared to the
wild-type rats were significant.
Extracellular signal-regulated kinase phosphorylation in the
renal cortex of Tg
Figure 5 shows the phosphorylated and total extracellular
signal-regulated kinase (ERK) levels in the renal cortex of the
Tg and wild-type rats determined by Western blot analysis.
The ratio of phospho-ERK level to total ERK level in the renal
cortex was significantly higher in Tg rats (4.770.5) than in
the wild-type rats (1.870.4).
Wild
Tg
Figure 3 | COX-2-dependent renal blood flow. Representative
COX-2 immunostaining in the renal cortex of Tg and wild-type (wild)
rats. Bar¼ 25mm. As shown by arrows, stronger COX-2 staining was
observed in the Tg group than in the wild group.
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Figure 2 | Renal cortical COX-2 expression. (a) Renal cortical COX-2
mRNA expression measured by real-time PCR and (b) representative
Western blotting and quantitative analysis of COX-2 protein
expression in Tg rats (n¼ 6) and wild-type rats (wild, n¼ 6).
*Po0.05 versus wild.
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Figure 4 | COX-2-dependent renal blood flow. (a) Change in
renal blood flow assessed by electromagnetic flow probe measure-
ment and (b) percent (%) change in renal cortical blood flow assessed
by fiber-optic blood flow measurement before (0 ng/g bw NS398)
and after administration of 1 and 10 ng/g
bw NS398 to Tg rats (n¼ 6, K) and wild-type rats (n¼ 4, J).
*Po0.05 versus 0 ng/g bw NS398, wPo0.05 versus the response
in wild-type rats.
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Figure 5 | Representative Western blotting of phosphorylated
ERK and total ERK and quantitative analysis by the ratio of
phosphorylated ERK to total ERK in the renal cortex from Tg rats
(n¼ 6) and wild-type rats (wild, n¼ 6). *Po0.05 versus wild.
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DISCUSSION
Transgenic expression of hProRenRc in rats did not affect
MAP, urinary sodium excretion, or rProRenRc levels.
However, macula densa COX-2 expression was significantly
higher in the Tg rats than in the wild-type rats, and the
increased COX-2 expression significantly contributed to the
regulation of renal cortical blood flow. These results suggest
that hProRenRc expression causes an increase in expression
and function of macula densa COX-2 independently of blood
pressure or urinary sodium excretion.
When prorenin binds to the prorenin receptor, two
important signals are thought to occur. One signal is the
non-proteolytic activation of prorenin: prorenin undergoes a
conformational change that includes exposure of its enzyma-
tically active site, and the activated prorenin stimulates the
renin–angiotensin system (RAS).9 The other signal is an increase
in mitogen-activated protein kinase (MAPK)-dependent in-
tracellular transduction that is independent of the RAS.8,10
Thus, enhancement of macula densa COX-2 expression by
hProRenRc is thought to be mediated through both a RAS-
dependent mechanism and a RAS-independent mechanism.
A recent study showed that angiotensin II stimulates renal
COX-2 mRNA expression in 5/6 renal-ablated rats.11 Human
ProRenRc may stimulate renal COX-2 mRNA expression
through an increase in angiotensin II levels owing to RAS
activation. In the present study, however, plasma angiotensin
II levels were similar in the Tg and wild-type rats. In addi-
tion, Cheng et al.12 clearly demonstrated that angiotensin II
attenuates renal COX-2 expression localized to the cortical
thick ascending limb of Henle’s loop cells in the region of the
macula densa in the rats. It is therefore unlikely that the RAS
activation contributes to the increase in macula densa COX-2
expression by hProRenRc. Low-chloride medium stimulates
COX-2 expression in primary cultured cortical thick ascend-
ing limb of Henle’s loop cells13 and a macula densa cell line14
through phosphorylation of the three major MAPK path-
ways, p38, Jun N-terminal kinase, and ERK, suggesting that
MAPK pathways play an important role in the expression
of COX-2 localized to the region of macula densa. In the
present study, the ratio of phospho-ERK to total ERK
was significantly increased in the renal cortex from Tg rats
compared to wild-type rats, suggesting that hProRenRc may
stimulate the ERK activation. Therefore, phosphorylation
of the MAPK pathways by hProRenRc can mediate the
upregulation of macula densa COX-2 expression observed in
the present study. Further studies are needed to clarify the
mechanism of the upregulation of macula densa COX-2 by
hProRenRc.
As COX-2 mediates the kidney prorenin synthesis induced
by a low-salt diet,15 increased levels and/or activity of macula
densa COX-2 can activate RAS and lead to blood pressure
elevation and a decreased urinary sodium excretion. In the
present study, however, both the blood pressure and urinary
sodium excretion of the Tg rats were similar to the values in
the wild-type rats, and the plasma renin activity, plasma
angiotensin II levels, and kidney angiotensin II levels of
4-week-old Tg rats were similar to those of 4-week-old wild-
type rats. Thus, it appeared that the plasma or kidney RAS of
the Tg rats is not activated at 4 weeks of age. Nevertheless,
renal cortical ERK was activated in the Tg rats compared to
the wild-type rats. Because of the high homology between the
amino-acid sequences of rProRenRc and hProRenRc, rat
prorenin is able to bind to hProRenRc. Our preliminary
study using COS-7 cells that expressed hProRenRc showed
that rat prorenin is capable of binding to hProRenRc but
does not enzymatically activate prorenin. The maximum
binding of hProRenRc to rat prorenin was 70% of the maxi-
mum binding of hProRenRc to human prorenin, and the
Kd value of rat prorenin binding to hProRenRc was 3 nmol/l
and approximately two-fold higher than the Kd of human
prorenin binding to hProRenRc. In the presence of rat
prorenin, however, sheep angiotensinogen was not converted
to angiotensin I in the medium of COS-7 cells that expressed
hProRenRc. Therefore, transgenic expression of hProRenRc
was capable of stimulating the RAS-independent intracellular
signals, but could not activate the RAS, because of compe-
titive inhibition of rProRenRc binding to rat prorenin by
hProRenRc. This may account for no activation of the RAS
despite increased direct actions of prorenin in the Tg rats.
In the present study, the clearance method and electro-
magnetic flow probe measurements confirmed a similar
baseline renal plasma flow in wild-type and Tg rats despite
enhanced COX-2 expression in the renal cortex of Tg rats.
These results suggest that some compensative mechanisms
worked to keep the renal plasma flow constant against
increased COX-2 expression. Therefore, COX-2 inhibition
with NS398 caused a significant decrease in renal cortical
blood flow only in Tg rats, which had an increased level of
macula densa COX-2.
In conclusion, transgenic expression of hProRenRc
resulted in stimulation of the expression and activity of
macula densa COX-2. Thus, hProRenRc may influence the
macula densa-dependent renal microcirculation by regulating
COX-2 expression.
MATERIALS AND METHODS
Plasmid DNA
These experiments were performed in accordance with the guide-
lines and practices established by the Keio University Animal Care
and Use Committee. hProRenRc (GenBank accession number
AF291814; nt 73–1301) plasmid vector, designated pCAGGS-
hProRenRc, was used. The details of its use, including its
construction, have been described previously.16 Briefly, we con-
structed an expression vector by introducing a CAG promoter that
comprises an AG promoter with a cytomegalovirus immediate early
gene enhancer and rabbit b-globin gene terminator sequences
including a polyadenylation signal. This vector, designated
pCAGGS-hProRenRc, ubiquitously exhibited high-level production
of hProRenRc in various organs.
Generation of the transgenic rats
Transgenic rats were generated by pronuclear microinjection of ferti-
lized Crj:Wistar rat eggs and reimplantation into pseudopregnant
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Crj:Wistar foster mothers. Six foster mothers carried 31 pups
to term, three of which carried the transgene, as demonstrated by
PCR analysis of DNA obtained from tail blood. Two of these
founders transmitted the transgene to their progeny, and the
transgenic lines hProRenRc no. 21 line and no. 29 line were
established. Transgene of hProRenRc was ubiquitously observed in
the brain, heart, kidney, liver, aorta, arteries, testis, lung spleen,
pancreas, adipose tissue, adrenal gland, ovary, and uterus, as shown
in Figure 1. The no. 21 line was used for the present study. Arterial
pressure was determined under the unrestricted and untethered
condition in 4-week-old rats using a telemetry device inserted into
the abdominal aorta, and the 24-h urine was collected in metabolic
cage. To determine p-aminohippurate sodium clearance as a renal
plasma flow, renal clearance study was performed under anesthesia
in the rats continuously infused with isotonic saline solution
containing 1% albumin and 1.5% p-aminohippurate sodium
(Merck & Co., Inc., Whitehouse Station, NJ, USA) at a rate of
20 ml/min, as described previously.17 Two groups of rats (n¼ 6 each)
were used in this series of experiments: a wild-type group born of
the hProRenRc line but to which the hProRenRc gene had not been
transmitted (wild), and a group of hProRenRc gene-transgenic (Tg)
rats. We decapitated six rats of each group to obtain the blood and
kidneys. Immediately after decapitation, a 3-ml blood specimen was
collected into a tube containing 30 ml of ethylenediaminetetra-
acetic acid (500 mM), 15 ml of enalaprilat (1 mM), and 30 ml of
o-phenanthroline (24.8 mg/ml) and pepstatin (0.2 mM), and plasma
samples were obtained by centrifugation. Plasma renin activity was
determined with a radioimmunoassay coated-bead kit (Dinabott
Radioisotope Institute, Tokyo, Japan). For the determination of
kidney angiotensin II content, the removed kidney was weighed,
placed in ice-cold methanol (10% wt/vol), homogenized with a
chilled glass homogenizer, and centrifuged. The supernatant was
then dried and reconstituted in 4 ml of 50 mM sodium phosphate
buffer containing 1% albumin. Plasma and reconstituted samples
from the kidneys were extracted with a Bond-Elut column
(Analytichem, Harbor City, CA, USA), and the eluents were
evaporated to dryness and reconstituted in angiotensin peptide
assay diluent. The angiotensin II content was quantitatively
determined by radioimmunoassay using rabbit anti-angiotensin II
antiserum (Arnel, New York, NY, USA). The urine samples were
collected in a metabolic cage, and the urinary concentration of
prostaglandin E2 was determined by radioimmunoassay using a
[125I] radioimmunoassay kit (PerkinElmer Life Sciences Inc.,
Boston, MA, USA) after the extraction by conventional methods
and subsequent purification on Bond-Elut Si columns (Analytichem
International, Harbor City, CA, USA).
Quantitative analysis of mRNA
As described previously,9 total RNA from part of the renal cortex
removed from each animal was extracted with an RNeasy Mini Kit
(QIAGEN KK, Tokyo, Japan), and real-time quantitative reverse
transcriptase-PCR (RT-PCR) was performed by using the TaqMan
One-Step RT-PCR Master Mix Reagents Kit with an ABI Prism 7700
HT Detection System (Applied Biosystems Inc., Foster City, CA,
USA) and probes and primers for rat genes encoding the following:
COX-2 (forward, 50-TGTTCGCATTCTTTGCCCA-30; reverse, 50-TA
AGTCCACTCCATGGCCCA-30; probe, 50-FAM-TCAGAAGCGAGG
ACCTGGGTTCACC-TAMRA-30); rProRenRc (forward, 50-CATT
CGACACATCCCTGGTG-30; reverse, 50-AAGGTTGTAGGGACTTT
GGGTG-30; probe, 50-FAM-AAGTCAAGGACCATCCTTGAGAC
GAAACAA-TAMRA-30); hProRenRc (forward, 50-AGATGACATGT
ACAGTCTTTATGGTGG-30; reverse, 50-TGCTGGGTTCTTCGCTT
GT-30; probe, 50-FAM-TTTGACACCTCCCTCATTAGGAAGACAA
GGACT-TAMRA-30); and glyceraldehyde-3-phosphate dehydro-
genase (forward, 50-TGACAACTCCCTCAAGATTGTCA-30; reverse,
50-GGCATGGACTGTGGTCATGA-30; probe, 50-FAM-TGCATCCTG
CACCACCAACTGCTTAG-TAMRA-30).
In situ hybridization
Renal localization of the transgene was assessed by in situ
hybridization, as described previously.18 Briefly, digoxigenin-labeled
cRNA antisense and sense probes were synthesized using a 600-bp
fragment of the AF291814 as template.
Western blotting of renal cortex
Western blot analyses were performed as reported previously.17
Briefly, the renal cortex was lysed in Tris (25 mmol/l) containing
NaCl (150 mmol/l), glycerol (5%), and protease inhibitor (1 tablet/
25 ml buffer), and after centrifugation at 10 000 g for 5 min followed
by centrifugation at 24 000 g for 30 min, the supernatant was
collected and subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. The proteins were transferred to polyvinylidene
difluoride membranes, and after blocking the blots overnight with
phosphate-buffered saline containing 5% bovine albumin and 0.5%
Tween 20, they were incubated for 16 h with mouse monoclonal
anti-rat COX-2 antibody (1:1000 dilution; Exalpha Biologicals,
Watertown, MA, USA), mouse monoclonal anti-phospho-44/42
MAPK (E10) antibody that crossreacts with rat phosphorylated
ERK1 and 2 (1:800 dilution; Cell Signaling Technology, Beverly, MA,
USA), or mouse monoclonal anti-a-tubulin antibody (1:500
dilution; EMD Biosciences, La Jolla, CA, USA). Immunoreactivity
was determined by horseradish peroxidase-conjugated donkey anti-
mouse antibody and an enhanced chemiluminescence reaction,
and the quantitative analyses were performed with Image 1D
(Pharmacia, Peapack, NJ, USA).
Immunohistochemical evaluation
Immunohistochemical staining for COX-2 was performed as
reported previously.17 Briefly, part of the kidney was fixed in 4%
paraformaldehyde phosphate buffer solution before paraffin embed-
ding, and deparaffinized sections were pretreated with proteinase K.
The sections were then boiled in citrate buffer with microwaves to
unmask antigenic sites, and endogenous biotin was blocked with a
biotin-blocking system (X0590; DAKO Corp., Kyoto, Japan). Next,
the sections were immersed in 0.3% H2O2 in methanol to inhibit
endogenous peroxidase and then precoated with 1% nonfat milk in
phosphate-buffered saline to block nonspecific binding. Polyclonal
rabbit anti-COX-2 antibody (160116, Cayman Chemical, Ann
Arbor, MI, USA) (1:200–500 dilution) was used as the primary
antibodies, and a biotinylated polyclonal goat anti-rabbit antibody
(1:500 dilution) was applied as the second antibody. Immunoreac-
tion was performed with a Vectastain ABC-Elite kit (Vector
Laboratories, Burlingame, CA, USA) and visualized with 0.02%
30,30-diaminobenzidine tetrahydrochloride as a substrate, and then
lightly counterstaining with hematoxylin.
Measurement of renal blood flow and renal cortical
blood flow
The effect of the COX-2 inhibitor NS398 (Cayman Chemical, Ann
Arbor, MI, USA) on renal cortical blood flow was assessed as
reported previously.17 Briefly, rats were anesthetized with intraperi-
toneal pentobarbital sodium (50 mg/kg). The right femoral artery
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was cannulated, and the cannula was connected to a computer
system (MacLab/8s, AD Instruments, Nagoya, Japan) via a pressure
transducer to monitor arterial pressure. The right carotid artery was
also cannulated to provide separate access for intra-arterial bolus
doses of NS398. The left kidney was exposed by a flank incision and
placed in a Lucite cup to stabilize it. A needle flow probe (500-mm
diameter) connected to a laser-Doppler flowmeter (FloC1-Twin;
Omegawave, Tokyo, Japan) was inserted into the kidney mass to a
depth of 1 mm to position its tip in the superficial cortex, and used
to measure relative changes in renal cortical blood flow. In addition,
a small-diameter, noncannulating, and factory-precalibrated electro-
magnetic flow probe (1RB2949; Transonic Systems Inc., Ithaca, NY,
USA), connected to a transit time flowmeter module (D-79232;
Transonic Systems Inc.), was vertically fitted around the left renal
artery to measure renal blood flow continuously. The rats were given
intra-arterial bolus injections (100 ml) of increasing doses of NS398
(0, 1, and 10 ng/g) at 10-min intervals.
Statistical analyses
Within-group statistical comparisons were made by one-way
analysis of variance for repeated measures followed by the
Neuman–Keuls post hoc test. Differences between two groups were
evaluated by two-way analysis of variance for repeated measures
combined with the Newman–Keuls post hoc test. A P-value ofo0.05
was considered significant. Data are reported as means7s.e.m.
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